Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

Wang,Yang; Liu,Shuang; Chen,Yu; Zheng,Sujun; Zhou,Li; Hua,Tsen; Sui,Shaofei; Lu,Fengmin; Duan,Zhongping

doi:10.3892/etm.2015.2855

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

Authors:
- Yang Wang
- Shuang Liu
- Yu Chen
- Sujun Zheng
- Li Zhou
- Tsen Hua
- Shaofei Sui
- Fengmin Lu
- Zhongping Duan
View Affiliations

Affiliations: Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, P.R. China, R&D Center Asia Pacific, Qiagen (Shenzhen) Co., Ltd., Shenzhen, Guangdong 518000, P.R. China, Department of Microbiology and Infectious Disease Center, Peking University Health Science Center, Beijing 100191, P.R. China
Published online on: November 12, 2015 https://doi.org/10.3892/etm.2015.2855
Pages: 117-123
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The emergence of entecavir (ETV) resistance is rare, particularly in a longitudinal study. The aim of the present study was to characterize the evolution of ETV‑resistant variants during antiviral therapy using entecavir monotherapy followed by ETV‑adefovir dipivoxil (ADV) combination therapy. The study included a prospective cohort of 53 consecutive chronic hepatitis B (CHB) patients. During the 60‑month period of ETV therapy, 2 patients exhibited ETV resistance and their medical records were comprehensively reviewed. A total of 25 consecutive serum samples were regularly collected from the 2 patients. All the samples were used to characterize the evolution of the polymerase gene mutations using pyrosequencing. The linkage of the variants was analyzed from 87 reverse transcriptase sequences of 3 selective samples using clone sequencing. The 2 patients presented with viral breakthrough during ETV monotherapy. In patient A, the rtL180M, rtS202G and rtM204V mutant variants were detected using pyrosequencing prior to virological breakthrough. Although the viral load declined following the administration of ADV, the ETV‑resistant variants were persistently dominant in the viral populations. In patient B, the rtL180M, rtM204I and rtM204V mutants were present in ~70, 30 and 10% of the viral populations, respectively, at the time of study entry. In addition, rtT184F was present in ~20% of the viral population during virological breakthrough, at month 24. The rtL180M, rtT184F and rtM204V were predominant during the combination treatment. Clonal analysis further revealed that the rtS202G or rtT184F was in all cases co‑localized with rtL180M and rtM204V in any single virus isolate clone. The results of the present study indicate that the addition of ADV therapy with ETV for treating ETV‑resistant mutation may not inhibit the replication of ETV‑resistant variants that developed previously in lamivudine-treated CHB patients.

View Figures

View References

1	Peng CY, Chien RN and Liaw YF: Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 57:442–450. 2012. View Article : Google Scholar : PubMed/NCBI
2	Liaw YF and Chu CM: Hepatitis B virus infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
3	Buti M: HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide analogs? Liver Int. 34(Suppl 1): 108–111. 2014. View Article : Google Scholar : PubMed/NCBI
4	Viganò M, Mangia G and Lampertico P: HBeAg-negative chronic hepatitis B: Why do I treat my my patients with nucleos(t)ide analogs? Liver Int. 34(Suppl 1): 120–126. 2014. View Article : Google Scholar : PubMed/NCBI
5	Dienstag JL, Goldin RD, Heathcote EJ, et al: Histological outcome during long-term lamivudine therapy. Gastroenterology. 124:105–117. 2003. View Article : Google Scholar : PubMed/NCBI
6	Zoulim F and Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 137:1593–1608, e1-e2. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lok AS and McMahon BJ: Chronic hepatitis B: update 2009. Hepatology. 50:661–662. 2009. View Article : Google Scholar : PubMed/NCBI
8	European Association For The Study of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012. View Article : Google Scholar : PubMed/NCBI
9	Liaw YF, Kao JH, Piratvisuth, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lok AS, Zoulim F, Locarnini S, et al: Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 46:254–265. 2007. View Article : Google Scholar : PubMed/NCBI
11	Kobashi H, Fujioka S, Kawaguchi M, et al: Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int. 3:403–410. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tenney DJ, Rose RE, Baldick CJ, et al: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 49:1503–1514. 2009. View Article : Google Scholar : PubMed/NCBI
13	Tenney DJ, Levine SM, Rose RE, et al: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 48:3498–3507. 2004. View Article : Google Scholar : PubMed/NCBI
14	Villet S, Ollivet A, Pichoud C, et al: Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 46:531–538. 2007. View Article : Google Scholar : PubMed/NCBI
15	Lee HW, Kim HJ, Hong SP, et al: Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient. Intervirology. 55:380–384. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lee GH, Inoue M, Toh JK, et al: Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. Liver Int. 33:642–646. 2013. View Article : Google Scholar : PubMed/NCBI
17	Tenney DJ, Rose RE, Baldick CJ, et al: Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 51:902–911. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ko SY, Kim BK, Kwon SY, et al: Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol. 18:6437–6446. 2012. View Article : Google Scholar : PubMed/NCBI
19	Degertekin B and Lok AS: Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used? J Hepatol. 48:892–894. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lindström A, Odeberg J and Albert J: Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol. 42:4788–4795. 2004. View Article : Google Scholar : PubMed/NCBI
21	Goodman ZD: Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 47:598–607. 2007. View Article : Google Scholar : PubMed/NCBI
22	Pallier C, Castéra L, Soulier A, et al: Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 80:643–653. 2006. View Article : Google Scholar : PubMed/NCBI
23	Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C and Pawlotsky JM: Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology. 49:50–59. 2009. View Article : Google Scholar : PubMed/NCBI
24	Chayama K, Suzuki Y, Kobayashi M, et al: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 27:1711–1716. 1998. View Article : Google Scholar : PubMed/NCBI
25	Deng XL, Li QL and Guo JJ: Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes. 47:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
26	Guo JJ, Li QL, Shi XF, et al: Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res. 81:180–183. 2009. View Article : Google Scholar : PubMed/NCBI
27	Lee JH, Cho Y, Lee DH, et al: Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 58:1730–1737. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ono A, Suzuki F, Kawamura Y, et al: Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 57:508–514. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhao P, Wang C, Huang L, Xu D and Li T: Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 96:100–104. 2012. View Article : Google Scholar : PubMed/NCBI
30	Sherman M, Yurdaydin C, Simsek H, et al: Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology. 48:99–108. 2008. View Article : Google Scholar : PubMed/NCBI
31	Colonno RJ, Rose R, Baldick CJ, et al: Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 44:1656–1665. 2006. View Article : Google Scholar : PubMed/NCBI
32	Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK and Lok AS: Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 44:703–712. 2006. View Article : Google Scholar : PubMed/NCBI
33	Zoulim F: Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist? Hepatology. 44:1404–1407. 2006. View Article : Google Scholar : PubMed/NCBI
34	Ijaz S, Arnold C, Dervisevic S, et al: Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol. 80:1160–1170. 2008. View Article : Google Scholar : PubMed/NCBI
35	Villeneuve JP, Durantel D, Durantel S, et al: Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 39:1085–1089. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chang TT, Liaw YF, Wu SS, et al: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (Baltimore, Md.). 52:886–893. 2010. View Article : Google Scholar : PubMed/NCBI